Trial Profile

A Registrational Trial for NRX-101 in the Treatment of Chronic Pain

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 01 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cycloserine/lurasidone (Primary)
Indications Pain
Focus Registrational; Therapeutic Use
Sponsors NRx Pharmaceuticals

Most Recent Events

01 Nov 2023 New trial record
26 Oct 2023 According to a NRx Pharmaceuticals media release, company's further alignment with the FDA Division of Anesthesiology, Addiction Medicine, and Pain Medicine in connection with the development of NRX-101 for treatment of Chronic Pain.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com